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ABSTRACT
Objective. Patients with Behçet’s dis-
ease (BD) constantly complain of fa-
tigue and many have problems with 
poor sleep. This ultimately has a major 
impact on all aspects of normal living. 
To attempt to understand this, Artifi-
cial Intelligence (AI) was used to iden-
tify potential biomarkers. These were 
alpha-melanocyte stimulating hormone 
(α-MSH), vasoactive intestinal peptide 
(VIP) and some inflammatory cytokines. 
We assessed the association of fatigue, 
quality of sleep and disease activity with 
circulating concentration of α-MSH, 
VIP and inflammatory cytokines. 
Methods. There were 127 partici-
pants, 97 BD patients, and 30 healthy 
controls (HC). All completed the Mul-
ti-Dimensional Assessment of Fatigue 
questionnaire (MAF) and the Pitts-
burgh Sleep Quality Index (PSQI) on 
the day of their clinical assessment. 
Enzyme-linked immunosorbent assays 
(ELISA) were used to evaluate the se-
rum concentrations of α-MSH, VIP 
and cytokines (IL-1β, IL-6, IL-10, and 
TNF-α). 
Results. 64% of BD patients experi-
enced high fatigue scores, and 63% 
had poor quality of sleep. When BD 
and HC were compared the MAF and 
PSQI scores as well as the serum 
concentrations of α-MSH, VIP, and 
IL-6 were significantly higher in BD 
(p values were: 0.001, 0.001, 0.001, 
0.004 and 0.036, respectively). Both 
α-MSH and IL-6 had significant im-
pact on MAF and PSQI. Interestingly, 
VIP had a significant influence on 
PSQI and disease activity, but not on 
MAF. 
Conclusion. A better understanding of 
these complex clinical and biochemical 
interactions between α-MSH, VIP and 
IL-6 might lead to the development of 
novel approaches to manage fatigue 
and sleep disorders as well as disease 
activity in BD patients.
Introduction 
Fatigue and disturbed sleep patterns are 
frequent symptoms in BD. They have a 
major impact on patients’ psychology, 
social well-being, disease activity and 
quality of life (QoL) (1, 2). Medically, 
fatigue is often unexplained and BD 
patients often have difficulty in de-
scribing fatigue symptoms which may 
or may not be related to disease activ-
ity and/or drugs. It causes physical and 
psychological problems, which may be 
exacerbated by secondary contributory 
factors including depressive mood, 
sleep disturbances and an unhealthy 
lifestyle (3). Studies using fatigue 
questionnaires have shown that BD pa-
tients tend to have high fatigue scores 
throughout life (4-6). Fatigue is report-
ed to be a common feature of a wide 
variety of conditions including chronic 
inflammation, infectious, neurological 
and psychiatric diseases and cancer 
(7). Furthermore, the quality of sleep is 
another major problem in BD patients 
that might have association with fa-
tigue and the complexity of symptoms 
and signs of the BD activity (6). Anxi-
ety and depression might also cause 
negative effects on the quality of sleep 
in BD (8). There is no specific biologi-
cal molecule/biomarker to assess fa-
tigue and sleep disturbance in patients. 
At present sleep questionnaires are the 
most common method to measure the 
quality and pattern of sleep in adults. 
In this study, to understand why most 
of the BD patients are always tired, we 
used mathematical modelling to iden-
tify any known or novel proteins or 
peptides which may contribute to poor 
quality of sleep, the increase of fatigue 
and to active systemic problems in BD.
One of the key immune-pathological 
features of BD is the high level of pro-
inflammatory Th1 cytokines (IL-2, 
IL-12, IL-18, IL-27, and IFNγ), and 
Th2 cytokines (IL-2, IL-10, IL13 and 
TNFβ/LTα) which play important roles 
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in the onset and perpetuation of the 
disease (9, 10). Cytokines such as IL-
1, IL-6 and TNF-α are known to exert 
both paracrine and endocrine effects. 
Therefore, they mediate not only local 
but systemic responses to physiologi-
cal and/or pathological stimuli. Moreo-
ver, the serum levels of cytokines el-
evated in patients with fatigue and poor 
sleep (11). 
The α-MSH level in patients with 
chronic fatigue syndrome (CFS) was 
higher than in healthy groups and 
is considered to be caused partly by 
chronic stressful events (12). The au-
thors suggested that α-MSH could be 
a potential biological marker for the 
diagnosis of CFS, at least during the 
first 5 years after its onset. In addition, 
α-MSH level may be higher in fatigue 
related conditions such as insomnia, 
sleep apnoea and inflammatory dis-
eases caused by viral infections (12, 
13). The effects of α-MSH may be due 
to an immunomodulatory/immunosup-
pressive activity (14-16), and may act 
as a suppressor of IFN-γ, TNF-α, IL-1, 
IL-6, IL-8 and induces the immunosup-
pressive cytokine IL-10 (17). 
Vasoactive intestinal peptide (VIP), 
belongs to the secretin/glucagon su-
perfamily of molecules and functions 
as a hormone, neurotransmitter, neu-
rotrophic agent and immune modulator 
(18). It is important in limiting ongoing 
inflammatory and immune responses, 
preventing platelet aggregation and 
promoting resolution of inflammation, 
by downregulating a wide spectrum of 
inflammatory cytokines, chemokines 
and mediators of oxidative stress by 
influencing the Th1 to Th2 shift and 
suppressing pro-inflammatory activity 
through the Protein Kinase-A (PKA)/
Cyclic Adenosine 3’,5’-monophos-
phate (cAMP) pathway (19-21). Fol-
lowing severe infection and/or signifi-
cant physical exercise chronic fatigue 
may develop due to the loss of immu-
nological tolerance to vasoactive neu-
ropeptides (18).  
The mathematical modelling was done 
and indicated that α-MSH, VIP and 
inflammatory cytokines may be im-
portant molecules influencing fatigue, 
sleep and disease activity. Therefore, 
in this study, we investigated whether 
α-MSH, VIP and inflammatory cy-
tokines were similar in BD patients 
compared with healthy participants. 
We also scrutinised the association of 
these biological molecules with oral 
and genital ulceration activity as well 
as the Behçet’s disease current activ-
ity form (BDCAF). The BD patients’ 
prescribed medication was also as-
sessed and correlated with the study 
outcomes.
Materials and methods
This prospective study included a co-
hort of 100 BD patients diagnosed 
according to the International Study 
Group Criteria (ISG 1990) and Inter-
national Criteria of Behçet’s Disease 
(ICBD 2014) criteria. The convenience 
sampling method was used to recruit 
study participants. 3 patients were ex-
cluded from the study due to incomplete 
clinical information (44 males: 53 fe-
males; mean age: 38.9±1.20 years). 30 
healthy control participants (HC), (14 
males: 16 females; mean age: 34±2.17 
years) were invited and recruited to the 
study, and informed consents were ob-
tained from all the participants. 
Ethical approval for this study was 
granted by Queen Mary University of 
London Ethics of Research Committee 
(P/03/122) at Barts Health NHS Trust. 
BD and HC groups were divided into 
eight subgroups based on fatigue score 
and the Pittsburgh Sleep Quality Index 
(PSQI): (61; 62%) BD had high fatigue 
scores and (33; 34%) BD low fatigue 
scores, (5; 17%) HC had high fatigue 
scores and (25; 83%) HC low fatigue 
scores while (38; 63%) BD patients re-
ported poor PSQI, (22; 37%) BD had 
good PSQI, while (8; 27%) HC had 
poor PSQI and (22; 73%) HC had good 
PSQI.
Mathematical modelling for candidate 
molecules
We have applied an AI tool (THERA-
Metrics Discovery AG, Stans, Switzer-
land) to collect and analyse information 
on the disease and the potentially relat-
ed biomarkers. It is based on Compu-
tational Linguistics and Mathematical 
Graph Theory, a methodology defined 
to build a visual graph representation 
of knowledge. This software is a fully 
unbiased, data-driven system using 
peer-reviewed literature only, with no 
pre-defined knowledge structure, and 
automatically linking concepts gath-
ered on drugs, pathways and biological 
activities with the pathophysiological 
signs and symptoms of diseases, thus 
creating novel working hypotheses 
based on biological and biochemical 
reasoning (22).
Clinical investigations
1. Multi-Dimensional Assessment of  
   Fatigue (MAF)
MAF is a validated, patient self-report-
ed scale to assess fatigue score in the 
preceding week, consisting of 16 items 
covering four dimensions of fatigue: 1) 
severity, 2) distress, 3) interference in 
activities of daily living (e.g., house-
hold chores, cooking, bathing, dress-
ing, working, socialising, sexual activ-
ity, leisure/recreation, shopping, walk-
ing, and other exercise), 4) frequency 
and change during the previous week. 
The items are used to calculate scores 
for each of the four dimensions and 15 
of the 16 questions are used to calcu-
late the global fatigue index (GFI) (23). 
The GFI ranges from 1 (no fatigue) to 
50 (severe fatigue). In our cohort, the 
patients’ scores were ranged from 1 (no 
fatigue), 2-20 (low fatigue), and 21 and 
over were (high fatigue) group, this 
classification was based on our cohort 
cut-off score of 20 with sensitivity of 
88% and specificity of 76%. The sub-
groups are part of statistical analysis 
to interpret and explain the data, and 
to match the statistical analysis with 
PSQI subgroups in this study. 
2. The Pittsburgh Sleep Quality Index 
    (PSQI)
PSQI is a self-rated questionnaire 
which assesses the quality of sleep and 
disturbances over the last 4 weeks. A 
scale of 19 items produce seven “com-
ponent” scores; 1) subjective sleep 
quality, 2) sleep latency, 3) sleep du-
ration, 4) habitual sleep efficiency, 5) 
sleep disturbances, 6) use of sleeping 
medication, and 7) daytime dysfunc-
tion. A total PSQI score corresponding 
to the total of individual scores from 
the above seven components results in 
a range between (0-21), a score equal 
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to 5 or less indicated a good quality of 
sleep for each patient (1). The PSQI 
has a sensitivity of 89.6% and specific-
ity of 86.5% for identifying cases with 
sleep disorder, using a cut-off score of 
5 (24). 
3. Outcomes measurements of BD 
    activity
The clinical assessment of the BD co-
hort was carried out by using multiple 
outcome forms for monitoring patients 
in the 4 weeks prior to the clinic ap-
pointment; genital ulcer severity score 
(GUSS) and oral ulcer severity score 
(OUSS) forms (25) are validated tools 
to assess orogenital ulcers in BD pa-
tients that include the six ulcer charac-
teristics (number, size, duration, ulcer-
free period, pain and site). BD current 
activity form (BDCAF) is a well-estab-
lished tool for the assessment BD activ-
ity in the clinic, which scores the histo-
ry of clinical features on scale of 0-12: 
headache, mouth ulcer, genital ulcer, 
ocular symptoms, skin lesions, erythe-
ma nodosum, joint pain, joint swelling, 
blood vessel involvement, gastrointes-
tinal, and central nervous system com-
plications, which present over the four 
weeks prior to the day of assessment 
(26). This clinical information was re-
corded in the patients’ medical files by 
clinicians or a senior nurse on the day 
the patients were present at the clinic. 
Information related to the treatment for 
each patient (non-steroidal anti-inflam-
matory drugs [NSAIDs], colchicine, 
azathioprine, mycophenolate mofetil 
(MMF), biologic agents, and/or corti-
costeroids) was also recorded.
Laboratory investigations
Enzyme-linked immunosorbent assay 
(ELISA) to measure serum concentra-
tion of α-MSH, VIP and specific four 
cytokines.  
Blood was collected into 8mL vacu-
tainers containing gel (BD Vacutainer® 
System, Devon, UK), and gently mixed 
by inversion, on the day of patients’ 
clinical assessment. After centrifuged 
at 1000xg for 15min, the separated se-
rum samples were aliquoted in single-
use volumes to avoid multiple freeze-
thaw cycles and stored at -80ºC until 
use. Serum concentrations of α-MSH, 
VIP (BD: HC= 83:30), IL-1β, IL-6, IL-
10, and TNF-α (BD: HC= 52:30) were 
measured by ELISA, according to the 
manufacturer’s instructions (α-MSH; 
VIP; Cloud-Clone Corp, USA. Cy-
tokines: RandD Systems, bio-techne, 
Abingdon, UK). The standard curves 
were generated for both molecules as 
manufacturer’s instructions. The mini-
mum detectable dose (MDD) of human 
α-MSH and VIP were typically less 
than 48.8 pg/ml and 2.95 pg/ml respec-
tively.
The levels of IL-1β, IL-6, IL-10, 
and TNF-α were quantified by using 
“Quantikine” Kits. The minimum de-
tectable dose (MDD) of human IL-1β, 
IL-6, IL-10 and TNF-α were 1 pg/ml, 
0.7 pg/ml, 3.9 pg/ml, and 1.6 pg/ml re-
spectively. The subject samples were 
assayed in duplicate, values averaged 
and expressed as concentrations (pg/
ml) relative to a 6-point standard curve 
as recommended by the manufacturer.
Stop solution (2N sulfuric acid) was 
added to each well. The optical den-
sity of the samples was analysed us-
ing 96-well microplate reader (BMG 
LABTECH, OPTIMA software ver-
sion 2,00R3) set at the appropriate 
wavelengths for subtracting readings 
at 540 nm/570 nm from the readings 
at 450 nm. This subtraction step was 
done to correct the optical imperfec-
tions in the plate. The results averaged 
and expressed as concentrations (pg/
ml). The results from the laboratory 
tests included alpha-MSH, VIP, IL1β, 
IL6, IL10 and TNF-α serum concen-
tration which correlated statistically 
with the patients’ clinical information, 
included BDCAF, disease activity and 
the fatigue, quality of sleep, oral ulcer 
severity OUSS, and genital ulcer sever-
ity scores GUSS.
Statistical analysis
Descriptive statistics of data were 
computed as mean ± SD, median, 
minimum and maximum value and 
qualitative variables presented as num-
ber (%). The parametric comparisons 
between groups were analysed by In-
dependent sample t- test and ANOVA. 
Mann-Whitney test and Kruskal-Wal-
lis were used for non-parametric data. 
Spearman’s rank test and Pearson’s 
coefficient were used to analyse non-
parametric and parametric evalua-
tions, respectively. The cut off serum 
concentration for biological molecules 
were determined using receiver operat-
ing characteristic (ROC) curve analy-
sis. Accuracy was measured by the area 
under the ROC curve (AUC). An area 
of 1 represents a perfect test; an area of 
0.5 represents a worthless test. p-value 
<0.05 was considered statistically sig-
nificant. Regression analysis was also 
carried out and the Tables are presented 
in supplementary information.
Results 
Ninety-seven BD patients (44 males: 
53 females; mean age: 38.9±1.20 
years) and 30 healthy participants (14 
males: 16 females; mean age: 34±2.17 
years) were enrolled in this study. 
The participants were divided into 
eight subgroups; Group 1= 64% BD 
high fatigue score, Group 2= 36% BD 
low fatigue score, Group 3= 17% HC 
high fatigue score and Group 4= 83% 
HC low fatigue score, and Group 5= 
63% BD poor PSQI, Group 6= 37% 
BD good PSQI, Group 7= 27% HC 
poor PSQI and Group 8= 73% HC 
good PSQI.
Descriptive results and disease 
presentation
Sixty-four BD patients had active dis-
ease on the day of clinical assessment, 
(29; 30%) had oral ulceration, (26; 
27%) arthropathy, (20; 21%) skin le-
sions, (17; 18%) headaches and other 
central nerve system (CNS) symptoms, 
(4; 4%) genital ulceration, and (2; 2%) 
gastrointestinal tract (GIT) and (2; 2%) 
had vascular problems each. During 
this study none of the patients had any 
ocular symptoms (no ocular activity 
and/or the progress of ocular symptoms 
were controlled). In addition, none of 
the patients in this study had a positive 
pathergy test.
Colchicine and azathioprine were the 
most frequently prescribed medication 
in this cohort. (14; 15%) patients had 
colchicine alone, (7; 7%) patients had 
azathioprine alone, (5; 5%) had predni-
solone, (6; 6%) had MMF and (8; 8%) 
had adalimumab (humira). (4; 4%) BD 
patients were taking anticoagulants and 
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(6; 6%) were taking aspirin. The rest of 
BD patients were on combination ther-
apy outlined in (Table I). 
The average of the BDCAF score of BD 
patients in the last 4 weeks of clinical 
appointment was (4.1±1.6; mean±SD), 
8 patients scored 0 (no BD symptoms), 
10 patients had a score of 1 (only one 
symptom of BD), 12 patients had score 
of 2 and 3 each, 9 patients scored 4 and 
6 each, 13 patients had a score of 5, 7 
patients had a score of 7, and 2 patients 
scored 10 (Fig. 1).
There were no significant age and gen-
der differences between the patients 
and HC subjects (Table II). The aver-
age for the fatigue score in BD patients 
was (28.38±1.56; mean±SD) and the 
PSQI average for BD patients was 
(9.4±0.67; mean±SD) and both were 
statistically significant compared to 
HC groups (p=0.001), respectively. 
The α-MSH concentration (ng/ml) 
was significantly higher in BD patients 
compared to HC (p=0.001). In addi-
tion, there were significant differences 
of VIP concentration (pg/ml) between 
BD and HC (p=0.004). Table III dis-
plays the cytokines concentration in 
detectable serum samples of BD and 
HC participants. There was a statisti-
cally significant difference in the level 
of IL-6 cytokines between BD and HC 
groups (p=0.036). However, IL-1β, 
IL-10 and TNF-α were not significant 
between BD and HC, p values >0.05 
(Table II).
Fatigue and PSQI with demographic 
data and clinical outcomes
When BD and HC fatigue groups (4 
groups) were analysed based on gen-
der. In the BD group, 46 out of 53 
females had high fatigue scores com-
pared with 15 out of 33 males. In the 
HC group, there were 3 out of 16 fe-
males with high fatigue compared with 
2 out of 14 males. 
Statistical analysis using the Chi-
square test showed a significant dif-
ference between patients’ gender and 
fatigue (p=0.001) in BD, whereas there 
was no significant difference between 
the healthy group (p=0.337).
Both males and females in the BD and 
HC cohorts segregated into distinct 
groups reporting low or high fatigue. 
There was no significant difference in 
the MAF scores for BD and HC based 
on gender. However, female BD pa-
tients reported significantly higher 
levels of fatigue compared with HC 
females in the high fatigue group (Fig. 
2).
In BD, the BDCAF scores were sig-
nificantly higher between both fatigue 
groups (high: low) and PSQI groups 
(worse: good) (p=0.001 each), and 
with clinician rating of disease activ-
ity (p value; 0.001 and 0.005, respec-
tively). The BD fatigue groups (high: 
low) and PSQI groups (worse: good) 
had higher significant differences with 
OUSS and GUSS in patients (p values 
were: 0.001, 0.009, 0.006, and 0.018) 
respectively (Table IV).
Regression analysis was performed to 
Table I. The BD symptoms and immunosuppressive treatment at the time the serum sam-
ples were collected.
Systemic involvement  Patients (No; %)
Oral ulceration 29/97; 30%
Arthropathy 26/97; 27%
Skin lesions 20/97; 21%
Headaches and other central nerve system (CNS) symptoms 17/97; 18%
Genital ulceration 4/97; 4%
Gastrointestinal tract (GIT) 2/97; 2%
Vascular problems 2/97; 2%
Ocular lesions  Non
Positive pathergy test Non
Grouped treatment protocols
Colchicine and azathioprine 7/97; 7%
Colchicine and antidepressants 2/97; 2%
azathioprine and prednisolone  3/97; 4%
azathioprine and methotrexate  1/97; 1%
Mycophenolate mofetil and prednisolone  8/97; 8%
Mycophenolate mofetil and warfarin 2/97; 2%
Adalimumab and azathioprine 3/97; 4%
Infliximab and azathioprine 2/97; 2%
Adalimumab and Mycophenolate mofetil 2/97; 2%
Infliximab and prednisolone 2/97; 2%
Infliximab, azathioprine and colchicine 1/97; 1%
Infliximab, azathioprine and prednisolone 1/97; 1%
No medication  10/97; 10%
Fig. 1. Distribution of BDCAF scores in BD patients. 
8 patients scored 0 (where no BD symptoms), 10 patients had a score of 1 (only one BD symptoms out 
of 12), 12 patients scored 2 (two BD symptoms out of 12) and scored 3 (three BD symptoms) each, 9 
patients had a score of 4 (four BD symptoms out of 12) and a score of 6 (six BD symptoms out of 12) 
each, 13 patients scored 5 (five BD symptoms out of 12), 7 patients scored 7 (seven BD symptoms out 
of 12), and 2 patients had a score of 10 (ten BD symptoms out of 12). 
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test the influence of both BD symptoms 
(activity) and individual BD medica-
tion on fatigue and quality of sleep. 
Arthropathy was the only symptom 
that had a significant impact which in-
creased the fatigue score and amplified 
PSQI score. There were no correlations 
or impact of the immunomodulatory 
medication on both the fatigue score 
and PSQI score.
Fatigue and disease activity in BD 
patients 
Regression analysis was used to in-
vestigate the effect of the fatigue score 
(the predictor variable) on the BDCAF 
score (dependent variable). The out-
come of this regression was: R= 0.554; 
R2= 0.307; p=0.001, (Model 1; Table 
S1). The coefficient of the standardised 
beta value was 0.554. This indicates 
that fatigue in BD patients is signifi-
cantly associated with an increase in 
the BDCAF score in this cohort, by a 
percentage of 55% of the variance. Ad-
ditionally, the fatigue score (the predic-
tor variable) was using to evaluate its 
impact on the clinician rating of dis-
ease activity (dependent variable) was: 
R= 0.50; R2= 0.25; p=0.001 and beta 
value was 0.500, (Model 2; Table S1). 
This indicates that the fatigue score can 
increase the clinical disease activity by 
a 50% of the variance.
Quality of sleep and disease activity in 
BD patients
Model 3; Table S1 demonstrates that 
the regression analysis of PSQI (pre-
dictor variable) and BDCAF score 
(dependent variable). The result of 
this regression analysis was: R= 0.43; 
R2= 0.19; p=0.001, and beta value was 
0.432. This denotes that the PSQI is 
associated with an increase BDCAF 
score in BD by a percentage of 43% 
of variance. In addition, BD systemic 
activity (dependent variable) and PSQI 
(predictor variable): R= 0.37; R2= 0.14; 
p=0.01, indicates that the PSQI is re-
sponsible for increasing BD systemic 
activity by a 37% of the variance, 
(Model 4; Table S1).
Association of α-MSH and VIP serum 
concentration with fatigue, quality of 
sleep and clinical outcomes
The mean of α-MSH concentration 
was significantly greater in BD patients 
who had high fatigue score (3.26±0.45 
ng/ml) than those with low fatigue 
score (2.68±0.89 ng/ml) (p=0.01). In 
contrast, HC groups of high and low 
Table II. Clinical characteristics and study factors of BD patients and healthy controls.
Clinical factors BD patients HC participants p value
 (minimum value-maximum (minimum value-maximum
 value; median; mean ± SD) value; median; mean ± SD) 
Gender (M: F) 44:53 14:16 0.77
Age 20-68; 38.5; 38.9±1.20 21-60; 32; 36.1±2.17 0.163
BDCAF 0-10;3; 3.5±0.25 Not present -
OUSS 0-46;15; 14.8±1.29 Not present -
GUSS 0-31; 1; 4.35±1.1 Not present -
Systemic activity
    Active 64 Not present -
    Quiet 33 
 
Outcomes measures 
Fatigue score 7-48; 32.35; 28.38±1.56 1-30.4; 10.8; 12.36±1.77 0.001*
PSQI score 1-20; 11; 9.4±0.67 0-12; 4; 4.74±0.72 0.001*
α-MSH concentration (ng/ml) 1.4-4.2; 3.06; 3.02±0.078 1.5-2.2; 1.92; 1.93±0.03 0.001*
VIP   (pg/ml) 36.6-323; 141.7; 148±77 66-124; 106.7; 104.1±16 0.004*
Cytokines (pg/ml)
    IL-1β 0.21-.619; 0.29;0.36±0.1 0.044-3.9; 0.54; 1.13±0.5 0.339
    IL-6 0.37-2.77; 1.59; 1.58±0.3 0.18-0.90; 0.34; 0.44±0.1 0.036*
    IL-10 3.12-6.25; 3.56; 4.79±0.7 0.85-24.5; 7.31; 10.9±7.1 0.470
    TNF-α 0.61-26.1; 7.75; 9.57±4.1 0.09-16.8; 1.54; 2.41±0.9 0.152
PSQI: Pittsburgh sleep quality index; BDCAF: Behçet’s disease current activity form; OUSS: oral ulcer 
severity score; GUSS: genital ulcer severity score; α-MSH: alpha-melanocyte stimulating hormone; 
VIP: vasoactive intestinal peptide; Not present: these are healthy controls without any manifestations.
*p values <0.05.
Table III. Serum samples of BD and HC participants where cytokine concentration was 
detectable.
Cytokines (MDD) (pg/ml) No. of positive samples (BD) No. of positive samples (HC)
 [No. active BD: No. inactive BD] 
IL-1β   (1 pg/ml) 21/52 [13:6] 7/30
IL-6    (0.7 pg/ml) 47/52 [29:11] 4/30
IL-10  (3.9 pg/ml) 41/52 [29:8] 3/30
TNF-α (1.6 pg/ml) 23/52 [8:12] 17/30
MDD: minimum detectable dose.
Lowest detectable levels of cytokines on the standard curves are shown in pg/ml.
Fig. 2. Fatigue and quality of sleep in BD patients based on gender. 
Low fatigue groups (males and females) of BD had a significant difference compared with HC groups 
of low fatigue (p=0.019). Moreover, the PSQI was greater in BD with good and poor PSQI comparing 
with HC of good and poor PSQI (p=0.016 and p=0.008) respectively.
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fatigue scores showed no significant 
differences in α-MSH concentration 
(p=0.37). Additionally, there were 
higher significant differences between 
α-MSH in BD low fatigue and HC 
low fatigue (p=0.014), and between 
BD high fatigue and HC high fatigue 
groups (p=0.001). There was higher 
significant difference of VIP serum 
concentrations in BD and HC with low 
fatigue scores (p=0.001) (Fig. 3A).
In terms of quality of sleep, the signifi-
cant difference in α-MSH concentra-
tion was found between BD good and 
poor PSQI compared to HC (p=0.003, 
and p=0.001 respectively). The com-
parison of the VIP serum concentra-
tion in BD and HC between those with 
poor PSQI, and good PSQI groups had 
significant differences (p=0.016, and 
p=0.001 respectively) as shown in Fig-
ure 3B.
Pearson’s correlation coefficient was 
applied to investigate the correlation 
between the study clinical outcomes 
variables with α-MSH and VIP con-
centrations. There was a positive corre-
lation between α-MSH with PSQI, also 
between α-MSH with the fatigue score 
(R= 0.348, p=0.012 and R= 0.439, 
p=0.001, respectively). However, VIP 
concentration had a positive correla-
tion with the PSQI score (R= 0.349, 
p=0.016). In addition, OUSS, GUSS, 
and BDCAF scores had positive cor-
relations with the fatigue score and 
PSQI; p values were significant <0.05.
Fatigue score had a strong positive as-
sociation with PSQI, therefore, mul-
tiple regressions were performed to 
investigate PSQI questionnaire vari-
ables and fatigue scores. This showed 
that the day-time dysfunction and sleep 
quality questions were the main varia-
bles which had significant impact to in-
crease the fatigue score of BD patients 
(R= 0.749; p=0.001) and beta values 
were; 0.35 and 0.33, respectively (Ta-
ble S2). 
Based on the disease activity and the 
differences in α-MSH and VIP se-
rum concentration, the data shows 
that VIP was significantly associated 
with disease activity (p=0.019). The 
Mann-Whitney test was performed to 
compare BD symptoms with VIP con-
centrations, and the only significant 
Table IV. Clinical characteristics of BD patients and the differences between fatigue and 
PSQI groups.
Clinical outcomes Pt. Fatigue groups Pt. PSQI groups
 (mean±SE low fatigue: mean±SE (mean±SE good PSQI: mean±SE
 high fatigue (p values) worse PSQI (p values)
Fatigue score (15.5±0.7: 35.5±0.76) (18.2±1.7:34.2±1.6)
 p=0.001* p=0.001*
PSQI score (5.57±0.83: 11.7±0.72) (3.6±0.33:12.7±0.5)
 p=0.001* p=0.001*
BDCAF (1.66±0.27: 4.41±0.28) (2.1±0.42:4.24±0.4)
 p=0.001* p=0.001*






PSQI: Pittsburgh sleep quality index; BDCAF: Behçet’s disease current activity form; OUSS: oral ulcer 
severity score; GUSS: genital ulcer severity score.
*p values<0.05.
Fig. 3A. The differences of alpha-MSH and VIP serum concentration in fatigue groups of BD and 
HC participants. 
α-MSH concentrations were significantly greater in BD high fatigue than low fatigue score, also the 
significant was noticed between BD and HC of high and low fatigue. In contrast, HC groups of high 
and low fatigue scores showed no significant results in α-MSH concentration (p=0.37). There were 
significant differences between α-MSH of BD low fatigue and HC low fatigue (p=0.014), and between 
BD high fatigue and HC high fatigue groups (p=0.001). Significant differences of VIP serum concen-
trations were observed between BD and HC with low fatigue scores (p=0.001).
Fig. 3B. The differences of alpha-MSH and VIP serum concentration in PSQI groups of BD and HC 
participants. 
The significant differences based on α-MSH were found between BD of good and poor PSQI; also, 
between BD good and poor PSQI group and HC of good and poor PSQI group (p=0.003, and p=0.001) 
respectively. The VIP serum concentrations were higher in BD with good and poor PSQI groups com-
pared with HC of good and poor PSQI groups; p<0.05. 
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association noted was between BD 
patients who had arthropathy and CNS 
symptoms (mean serum VIP= 66 pg/ml 
and 156 pg/ml respectively; p=0.043).
ROC curve analysis suggests that the 
optimum α-MSH concentration cut-off 
point for BD patients with high fatigue 
was 2.89 ng/ml, had a sensitivity, spec-
ificity and accuracy of 79% 70% and 
0.774, respectively (95% confidence 
interval 0.639-0.902, p=0.001) (Fig. 
S1).
The single regression analysis illus-
trations that the association between 
fatigue score (dependent variable) and 
α-MSH (predictor variable) was sig-
nificant: R= 0.44; R2= 0.193; p=0.001. 
The beta value suggests that (α-MSH) 
is responsible for about 44% of the 
variance to increase the fatigue score 
(Model 5; Table S3). The VIP concen-
tration (predictor variable) does not 
have an impact on the fatigue score 
(dependent variable); p=0.152 (Model 
6; Table S3). 
The α-MSH concentration (predic-
tor variable) had a positive associa-
tion with PSQI (dependent variable): 
R= 0.35; R2= 0.121; p=0.012, (Model 
7; Table S3), and beta value suggests 
that the BD patients who had high se-
rum concentration of α-MSH to can 
increase score of PSQI (poor quality 
of sleep) by 35% of the variance. Also, 
the VIP concentration (predictor vari-
able) and PSQI (dependent variable) 
was significant: R= 0.343; R2= 0.112; 
p=0.018. The beta value suggests that 
the VIP concentration was responsible 
for more than 34% of variance to in-
crease score of PSQI (Model 8; Table 
S3).
Association of IL-6 and TNF-α with 
fatigue, quality of sleep and clinical 
outcomes 
The serum cytokines concentration 
did not illustrate any statistically sig-
nificant differences in HC of fatigue 
groups and PSQI groups. However, 
in BD patients the serum cytokine 
concentration of IL-6 was signifi-
cantly greater in low fatigue group 
than the patients of high fatigue group 
(3.02±2.19; p=0.007) (Table S4). How-
ever, the other cytokines IL-1β, IL-10 
and TNF-α did not show any statisti-
cal significance between the low and 
high fatigue groups. Furthermore, IL-
1β, IL-6 and IL-10 concentrations were 
very similar between PSQI groups of 
BD patients. 
IL-1β concentration was significant 
only in HC good PSQI group com-
paring with HC poor PQSI group 
(p=0.05). Moreover, BD of low fatigue 
had greater levels of IL-6 than HC low 
fatigue group (p=0.009). IL-10 concen-
tration was not significant between any 
of BD fatigue groups and PSQI groups 
nor between HC groups. P value of 
TNF-α concentration was 0.06 be-
tween BD and HC with high fatigue 
groups (Fig. 4A and 4B). 
Spearman’s correlation coefficient re-
vealed that α-MSH had a moderate 
negative correlation with IL-6 (R= 
-0.368, p=0.030), whereas, α-MSH 
had a positive correlation with TNF-α 
Fig. 4A. The differences of cytokines concentration in fatigue groups of BD and HC. 
BD low fatigue group had higher concentration of IL-6 than BD high fatigue group and HC fatigue 
groups (p=0.007 and p=0.009) each. TNF-α just failed to reach significance between BD high fatigue 
group and HC high fatigue group (p=0.06). IL-10 and IL-1β were not significant between BD and HC 
of fatigue groups.
Fig. 4B. The differences of cytokines concentration in PSQI groups of BD and HC. 
IL-1 β in HC of good and poor PSQI groups had a p=0.050. The mean value for IL-6 was greater in 
BD good PSQI than HC good PSQI group (p=0.08); however, the range for BD (Good PSQI) was wide 
so that the analysis just failed to reach significance. IL-10 was not significant between the most of the 
PSQI of BD and HC groups. p value of TNF-α concentration was not significant between BD groups 
of good and worse PSQI. 
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(R= 0.495, p=0.023). In addition, VIP 
did not show any statistical signifi-
cance (Table S5). 
Those cytokines; IL-1β, IL-6, IL-10, 
and TNF-α did not show any statisti-
cal significant with BD systemic ac-
tivity (p=0.690, p=0.656, p=0.734 
and p=0.137, respectively). However, 
TNF-α showed a positive significant 
correlation with BDCAF score (R= 
0.515, p=0.012).
ROC curve analysis suggests that 1.3 
pg/ml was the IL-6 cut off point of BD 
low fatigue group in this study, with 
a sensitivity, specificity and accuracy 
of 79%, 77% and 0.777, respectively 
(95% confidence interval 0.635-0.920; 
p=0.003) (Fig. S2).
Discussion 
Presently, there are no available bio-
markers to assist in the diagnosis or in 
treating fatigue or to improve the qual-
ity of sleep. In this study, most of our 
patients presented with fatigue and/or 
poor quality of sleep. It is therefore not 
surprising that quality of sleep pattern 
and daytime dysfunction items of the 
PSQI questionnaire had a significant 
impact on the fatigue score in patients 
with BD. The first question was ad-
dressed in this article is whether gender 
and age of patients had any association 
with fatigue and quality of sleep. Age 
appeared not to be a significant fac-
tor in either the BD or HC groups of 
fatigue or quality of sleep. However, 
gender was significant related to both 
fatigue and quality of sleep. Females 
with BD and the HC group had high-
er fatigue scores when compared to 
males. The explanation for the distinc-
tion between female and male scores 
may be related to the hormonal chang-
es in females (during menstrual cycle 
and menopause) increasing the risk of 
fatigue (27).
As mentioned above, fatigue was a 
common problem in this cohort, and 
was seen predominantly in patients 
who suffered from arthropathy. Ar-
thropathy is one of the most common 
manifestations in BD which contrib-
utes to reduced QoL (28). In addition, 
most the patients in this study also 
suffered from poor quality of sleep 
which may have contributed to further 
exacerbating their arthropathy induced 
pain. The BD systemic activity, OUSS, 
GUSS and BDCAF were found to be 
more severe when the fatigue and the 
poor quality of sleep scores increased. 
In addition, there is no specific medi-
cation that is routinely used to treat 
or relieve the fatigue experienced by 
patients that improves the quality of 
sleep. This study demonstrated that 
there was no association between any 
specific BD medication and the pa-
tients’ experience of either fatigue or 
quality of sleep scores. 
We also attempted to identify whether 
there was any association between the 
patients’ systemic activity, fatigue and 
quality of sleep with specific biological 
molecules. To this end we used math-
ematical modelling to identify likely 
molecules. These were α-MSH and 
VIP. In addition, we investigated cy-
tokines which are known to be associ-
ated with fatigue and sleep. 
Alpha-MSH is a neuroimmuno-modu-
lating peptide which has been found to 
be raised in the CSF (12). In previous 
studies, α-MSH serum concentrations 
were elevated during infective epi-
sodes or inflammatory disorders com-
pared with healthy controls (12, 29, 
30). α-MSH had a positive correlation 
with episodes of stress (31). Interest-
ingly in BD psychosocial stress is ap-
pears to be one of the possible triggers 
in the aetiopathogenesis of Behçet’s 
and it is also associated with episodes 
of relapse (2), despite the majority of 
patients in this study were white Brit-
ish, who tend to produce less melanin 
due to variations in their melanocyte-
stimulating hormone receptors (32). In 
this study, the results demonstrate that 
the α-MSH serum concentrations were 
higher in the BD fatigue groups and 
in PSQI group compared with healthy 
participants. The high circulating con-
centration of α-MSH may be due to 
its anti-inflammatory effect in active 
disease, and the use of immune-mod-
ulatory medication (33). An additional 
factor may have been the timing of the 
collection of samples which was taken 
during daylight hours (11am-4pm) 
in both cohorts. Several other studies 
have already established that α-MSH 
production is increased during daylight 
and during exposure to UV light (34, 
35).
When we further divided our BD co-
hort into those with high or low fatigue 
scores the α-MSH concentration for 
patients with high fatigue scores was 
(≥2.89 ng/ml), compared with BD pa-
tients with low fatigue scores. These 
results suggest that the level of α-MSH 
might be used to differentiate BD fa-
tigue groups (low and high fatigue). 
Biologically, VIP plays a role in the 
regulation of the immune cells to in-
hibit the inflammatory response. This 
function adds to its importance as a 
contender molecule to affect systemic 
activity in BD. The method of collec-
tion was standardised with patients at 
rest in the clinic as a recent study has 
detected that the salivary VIP con-
centration remarkably increased after 
a stress response induced by brief in-
tense exercise lasting minutes (36). 
Previous studies have suggested that 
the normal VIP level in blood meas-
ured by radio immunoassay (RIA) or 
recycling immunoaffinity chromatog-
raphy (RIC) was less than 100 pg/ml 
(37-39). However, both Luminex and 
ELISA methods used to measure lev-
els in human serum gave similar results 
with the VIP concentration; 95±5 pg/
ml and 100.4±45.7 pg/ml, respective-
ly. In addition, VIP concentration in 
healthy fasting participants were re-
ported as: 0-170 pg/ml or 0-190 pg/ml 
(40). In this study, the mean serum of 
VIP concentration of healthy controls 
was 104.1±16 pg/ml. However, the 
distribution of VIP serum concentra-
tion in BD patients was very variable, 
ranging (36 to >323 pg/ml) especially 
amongst inactive BD patients who had 
higher VIP concentration compared to 
active BD patients. The lowest levels 
of VIP tended to be more frequent in 
BD patients with arthropathy (mean= 
66 pg/ml), whereas BD patients with 
CNS symptoms had much higher lev-
els (mean= 156 pg/ml). This observa-
tion is in line with the findings of other 
groups (41). The heterogeneity in VIP 
concentration was also observed in 
patients who had immunomodulatory 
medication such as infliximab alone or 
combined with other medications but, 
interestingly, not prednisolone. Fur-
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thermore, our data observed a positive 
association of VIP with the quality of 
sleep in BD cohort.
The increased levels of pro-inflamma-
tory cytokines activate the hypothala-
mus and subsequently lead to “sickness 
behaviour”. This can disturb eating be-
haviour, mood states, with the feelings 
of discomfort and low energy (42). In 
the present study, the association be-
tween BD patients’ systemic activity, 
fatigue and quality of sleep with the 
serum concentration of some cytokines 
were investigated. It has found that 
IL-6 was the main cytokine component 
which was significantly different in BD 
patients compared with HC. This find-
ing supports other studies which con-
cluded that the dominant cytokine in 
auto-inflammatory diseases such as BD 
is IL-1β, and the secondary cytokine is 
IL-6 (43). We also found that IL-6 was 
higher in BD patients with low fatigue 
compared with the high fatigue group 
which might due to the effect of immu-
nomodulatory medication.
Moreover, previous studies reported 
that increased levels of IL-1β and 
TNF-α may be associated with fever, 
fatigue, and sleep disturbances (44). 
Our data indicated that the IL-10 and 
IL-1β serum concentrations were not 
significantly different between BD fa-
tigue and PSQI groups. TNF-α failed 
to demonstrate any significant differ-
ence between BD patients with in-
creased of fatigue and poor quality of 
sleep groups (Table S4). However, this 
may have been because most of the BD 
patients were using immunomodula-
tory medication which decreases the 
level of TNF-α and IL-1β. This may 
have contributed to masking the differ-
ences between the fatigue and quality 
of sleep groups in BD cohort.
The main limitation of this study is that 
it is based on an observational cross-
sectional design, with data collected 
from patients at a single point of time 
during the day, which did not allow us 
to investigate any diurnal changes. This 
may have played a role in masking the 
differences between the high and low 
fatigue groups. However, the current 
data has given us baseline informa-
tion to carry out prospective follow-up 
studies with a larger sample size. In 
addition, controlled clinical trials will 
be needed to provide more informa-
tion about the role of these molecules 
in BD.
In conclusion, in BD fatigue and poor 
quality of sleep both remain very chal-
lenging issues for both patients and 
attending physicians. In the present 
study, arthropathy in BD patients had 
a significant impact by increasing the 
fatigue score and causing poor quality 
of sleep. The complex interactions of 
α-MSH and VIP with IL-6 might lead 
to the development of novel approach-
es to treat symptoms of fatigue and 
sleeplessness in BD patients. The data 
also suggests that VIP might be used as 
a marker for CNS disease activity in 
BD patients. The findings indicate that 
further in vitro laboratory experiments 
in needed to understand the effect of 
α-MSH, VIP, and IL-6 on immune 
cells function in BD patients. It is im-
portant to test α-MSH, VIP, and IL-6 
in the context of any new medication 
proposed for the treatment of fatigue. 
Currently available treatments targets 
are IL-1β, and TNF-α and their recep-
tors. These are not completely suc-
cessful in treating patients. In contrast, 
IL-6 is a more interesting target for BD 
patients. We suggest that continued use 
of AI mathematical modelling methods 
can provide essential information in 
the analysis of complex physiological 
processes, which would support novel 
drug discovery.
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